KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results.

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

Elinzanetant reduced vasomotor symptoms frequency and severity in women with or at high risk of HR-positive breast cancer in the OASIS 4 trial.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.

During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.